Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by Sector Gamma AS

Sector Gamma AS cut its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 18.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 25,712 shares of the medical equipment provider’s stock after selling 6,000 shares during the quarter. Lantheus makes up 0.8% of Sector Gamma AS’s investment portfolio, making the stock its 29th biggest holding. Sector Gamma AS’s holdings in Lantheus were worth $2,300,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in LNTH. Wilmington Savings Fund Society FSB acquired a new stake in shares of Lantheus in the 3rd quarter valued at about $25,000. Kestra Investment Management LLC purchased a new stake in Lantheus during the 4th quarter valued at approximately $27,000. UMB Bank n.a. raised its stake in Lantheus by 31.5% during the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock valued at $50,000 after acquiring an additional 134 shares during the last quarter. World Investment Advisors LLC purchased a new stake in Lantheus during the 3rd quarter valued at approximately $60,000. Finally, Parkside Financial Bank & Trust raised its stake in Lantheus by 49.4% during the 4th quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider’s stock valued at $76,000 after acquiring an additional 280 shares during the last quarter. 99.06% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

LNTH has been the subject of several analyst reports. The Goldman Sachs Group initiated coverage on Lantheus in a research note on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective for the company. JMP Securities reaffirmed a “market outperform” rating and set a $112.00 price objective on shares of Lantheus in a research note on Tuesday, January 14th. StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Finally, Truist Financial increased their target price on Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research note on Thursday, February 27th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $132.86.

Lantheus Price Performance

LNTH opened at $98.85 on Friday. The stock has a market cap of $6.77 billion, a P/E ratio of 16.45 and a beta of 0.38. The stock’s 50 day simple moving average is $92.64 and its 200 day simple moving average is $96.70. Lantheus Holdings, Inc. has a 1-year low of $57.92 and a 1-year high of $126.89.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). The firm had revenue of $391.11 million during the quarter, compared to analyst estimates of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. Research analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Insider Buying and Selling

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the sale, the director now owns 440,399 shares in the company, valued at approximately $41,551,645.65. This represents a 10.76 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of Lantheus stock in a transaction on Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the sale, the chief financial officer now directly owns 113,860 shares of the company’s stock, valued at approximately $11,445,207.20. This represents a 8.07 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 64,109 shares of company stock worth $6,110,806 in the last quarter. Company insiders own 1.50% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.